mantle cell lymphoma (MCL)

March 12, 2020March 12, 2020

CLR 131 Shows Anti-tumor Activity, Safety in Difficult-to-treat B-cell Lymphoma Trial

News

Cellectar Biosciences has announced positive trial results demonstrating that its investigational therapy CLR 131 significantly reduced tumor activity, with tolerable safety, in B-cell lymphoma patients who received prior treatments. A “notable” ... Read more

February 4, 2020February 4, 2020

CAR T-cell Therapy KTE-X19 Under Review in Europe and US for Mantle Cell Lymphoma

News

The European Medicines Agency (EMA) has validated and is now reviewing Kite Pharma’s application requesting the approval of its investigational chimeric antigen receptor (CAR) T-cell therapy KTE-X19 for adult patients with relapsed or ... Read more

August 23, 2019

FDA Grants Priority Review to Zanubrutinib as Treatment for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review BeiGene‘s application requesting the approval of zanubrutinib for treating people with mantle cell lymphoma who received at least one ... Read more

August 2, 2019August 2, 2019

First Patient Dosed in Trial Testing Abexinostat-Imbruvica Combo for Advanced Lymphomas

News

Xynomic Pharma has initiated patient dosing in a Phase 1/2 trial testing its investigational therapy abexinostat, in combination with Imbruvica (ibrutinib), as a treatment for people with mantle cell lymphoma (MCL) and ... Read more

February 28, 2019

First Patient Dosed in Trial of ADCT-402/Imbruvica Combo for Advanced DLBCL, MCL

News

A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imbruvica (ibrutinib) for advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) has dosed the first patient. Patient ... Read more

September 20, 2018

Older Stem Cell Transplant Patients with Non-Hodgkin’s Lymphoma at Higher Risk of Death, Study Suggests

News

Stem cell transplant to treat non-Hodgkin’s lymphoma in patients older than 65 is as effective as it is in younger patients, but is associated with a higher risk of non-relapse ... Read more

October 3, 2017October 3, 2017

Rituxan Seen to Benefit Mantle Cell Lymphoma Patients After Stem Cell Transplant

News

A Phase 3 trial of Rituxan (rituximab) as a maintenance therapy in adults with mantle cell lymphoma after a stem cell transplant found that the treatment improved survival rates over four years. ... Read more

June 22, 2017

At Least Four-fifths of Leukemia and Lymphoma Patients Respond to TRG-1202 Combo Therapy, Researchers Report

News

Ninety-four percent of patients with chronic lymphocytic leukemia and 79 percent with mantle cell lymphoma responded to treatment with a combination of TGR-1202 (umbralisib), Imbruvica (ibrutinib), and TG-1101, according to updated Phase ... Read more

November 3, 2016

Cellectar Reveals Phase 2 Study Design for Investigational Therapy in Lymphoma, Myeloma Patients

News

Cellectar Biosciences has revealed the study design of an upcoming Phase 2 trial examining the investigational compound CLR 131 in multiple myeloma and a number of lymphoma subtypes. The study, which ... Read more